Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy for USA women at increased risk of fracture

M. Hiligsmann; S.A. Williams; L.A. Fitzpatrick; S. Silverman; R. Weiss; Jean-Yves Reginster

$Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy for USA women at increased risk of fracture$

Conference proceeding

Peer reviewed

Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy for USA women at increased risk of fracture

M. Hiligsmann, S.A. Williams, L.A. Fitzpatrick, S. Silverman, R. Weiss and Jean-Yves Reginster

Osteoporosis International, 30 (S2), S503-S504 (2019-07); World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Paris, France [FR], du 4 au 7 avril 2019

07/2019

Abstract

Human health sciences

Public health, health care sciences & services

Santé publique, services médicaux & soins de santé

Sciences de la santé humaine

Metrics

1 Record Views

Details

Title: Cost-effectiveness of sequential treatment with abaloparatide followed by alendronate vs. alendronate monotherapy for USA women at increased risk of fracture
Creators - without role: M. Hiligsmann
S.A. Williams
L.A. Fitzpatrick
S. Silverman
R. Weiss
Jean-Yves Reginster
Conference: Osteoporosis International, 30 (S2), S503-S504 (2019-07); World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases, Paris, France [FR], du 4 au 7 avril 2019
Publisher: Springer
Identifiers: 9952829308331
Academic Unit: King Saud University
Language: English
Resource Type: Conference proceeding